RxDoctor Payments Data

John Marenco, MD

Clinical Cardiac Electrophysiology · Springfield, MANPI 1669441374

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 66.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $7,780 and has fallen 79.5% since, to $1,592 in 2025.

$26,796in general payments, 2019–2025

Across 312 payments — averaging $85.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$18K
  • Medtronic$3K
  • Biotronik Inc.$2K
  • Boston Scientific$820
  • Novartis$523
  • Pfizer$439
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$9,11334%
  • Travel & lodging$4,61717%
  • Food & beverage$13,06649%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,796 in reported general payments places this provider in the 65th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$488,204
Medicare patients
1,697
Services billed
7,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$390,125
EntrestoSacubitril/Valsartan73$98,501
XareltoRivaroxaban75$92,977
MultaqDronedarone Hcl74$91,938
FarxigaDapagliflozin Propanediol20$20,964
Metoprolol Succinate202$4,357
Flecainide Acetate71$3,699
Rosuvastatin Calcium64$3,336
Diltiazem 24hr Er (La)Diltiazem Hcl20$2,733
Nadolol13$2,384
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$2,349
Atorvastatin Calcium97$1,686
Dilt-XrDiltiazem Hcl37$1,435
Propafenone Hcl12$1,136
Carvedilol96$1,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$439$390,125306 claims
NovartisEntresto$523$98,50173 claims
Johnson & JohnsonXarelto$238$92,97775 claims
Sanofi-aventis U.S. LLCMultaq$53$91,93874 claims
AstraZenecaFarxiga$246$20,96420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →